Ambroxol (ambroxol hydrochloride) tablets 0.03g. №20

active ingredient : ambroxol;

1 tablet contains ambroxol hydrochloride in terms of 100% substance – 30 mg;

excipients: potato starch; lactose, monohydrate; calcium stearate.

Drugs used for coughs and colds. mucolytic agents. Ambroxol.

ATX code R05C B06.

It has been preclinically proven that ambroxol hydrochloride increases the formation of the serous component of bronchial secretions. Ambroxol enhances the release of pulmonary surfactant by direct action on the pneumocyte (type II) in the alveoli and Clara cells in the bronchioles, and also stimulates ciliary activity, resulting in a decrease in sputum viscosity and improved excretion (mucociliary clearance). Improvement in mucociliary clearance has been proven during clinical and pharmacological studies.

Increased production of serous secretions and increased mucociliary clearance facilitate expectoration and reduce coughing.

In patients with chronic obstructive pulmonary disease who received ambroxol hydrochloride 75 mg extended-release capsules for 6 months, there was a significant reduction in the number of exacerbations compared with placebo at the end of 2 months of treatment. Patients treated with ambroxol hydrochloride had fewer days of illness and needed fewer days of antibiotic therapy. They also showed a statistically significant reduction in symptoms such as difficulty expectorating, coughing, dyspnea, and auscultatory sounds compared to placebo.

The local anesthetic effect of ambroxol hydrochloride was observed in a rabbit eye model, which can be explained by sodium channel blocking properties. In vitro studies have shown that ambroxol hydrochloride blocks neuronal sodium channels; binding was reversible and concentration dependent.

Ambroxol hydrochloride has shown anti-inflammatory effects in vitro. Thus, ambroxol hydrochloride significantly reduces the release of cytokines from mononuclear and polymorphonuclear blood cells and tissues.

As a result of clinical trials involving patients with pharyngitis, a significant reduction in pain and redness in the throat with the use of the drug has been proven.

Due to the pharmacological properties of ambroxol, pain was quickly relieved in the treatment of diseases of the upper respiratory tract, which was observed in the course of studies of the clinical efficacy of inhaled forms of ambroxol.

The use of ambroxol hydrochloride increases the concentration of antibiotics (amoxicillin, cefuroxime, erythromycin and doxycycline) in bronchopulmonary secretions and sputum. To date, no clinical significance of this fact has been identified.

Secretolytic therapy in acute and chronic bronchopulmonary diseases associated with impaired bronchial secretion and weakening of mucus movement.

The drug should not be used in patients with established hypersensitivity to ambroxol hydrochloride or to other components of the drug.